These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8902442)

  • 1. Effects of continuous percutaneous estradiol administration on skeletal turnover in postmenopausal women: a 1-year prospective controlled study.
    Cicinelli E; Cantatore FP; Galantino P; Rubini G; Cerundolo M; Balzano G; D'Aquino TM
    Eur J Obstet Gynecol Reprod Biol; 1996 Nov; 69(2):109-13. PubMed ID: 8902442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY; Weetman AP; Eastell R
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate].
    Collette J; Viethel P; Dethor M; Chevallier T; Micheletti MC; Foidart JM; Reginster JY
    Gynecol Obstet Fertil; 2003 May; 31(5):434-41. PubMed ID: 14567121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metabolism changes after transdermal estradiol dose reduction during estrogen replacement therapy: a 1-year prospective study.
    Cicinelli E; Galantino P; Pepe V; Popolizio A; Savino F; Balzano G; Epifani S; Cantatore FP
    Maturitas; 1994 Aug; 19(2):133-9. PubMed ID: 7968646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of menopause and hormone replacement therapy on bone alkaline phosphatase.
    Alexandersen P; Hassager C; Riis BJ
    Scand J Clin Lab Invest; 1995 Nov; 55(7):571-6. PubMed ID: 8633181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
    Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
    Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women.
    Berthold HK; Unverdorben S; Zittermann A; Degenhardt R; Baumeister B; Unverdorben M; Krone W; Vetter H; Gouni-Berthold I
    Osteoporos Int; 2004 Jun; 15(6):459-67. PubMed ID: 15205717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy.
    Hall GM; Spector TD; Delmas PD
    Arthritis Rheum; 1995 Jul; 38(7):902-6. PubMed ID: 7612039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment.
    Moore AE; Blake GM; Taylor KA; Rana AE; Wong M; Chen P; Fogelman I
    J Bone Miner Res; 2010 May; 25(5):960-7. PubMed ID: 19929434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of transdermal estrogen therapy on bone mass and turnover in early postmenopausal smokers: a prospective, controlled study.
    Välimäki MJ; Laitinen KA; Tähtelä RK; Hirvonen EJ; Risteli JP
    Am J Obstet Gynecol; 2003 Nov; 189(5):1213-20. PubMed ID: 14634543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women.
    García-Pérez MA; Moreno-Mercer J; Tarín JJ; Cano A
    Gynecol Endocrinol; 2006 Apr; 22(4):179-84. PubMed ID: 16723303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women.
    Huang AJ; Ettinger B; Vittinghoff E; Ensrud KE; Johnson KC; Cummings SR
    J Bone Miner Res; 2007 Nov; 22(11):1791-7. PubMed ID: 17620054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.